EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access · CC BY-NC 3.0

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

Pin-Nan Cheng, Ming-Lung Yu

Clinical and Molecular Hepatology · 2024

DOI: 10.3350/cmh.2024.0115 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Pin-Nan Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicCardiovascular DiseasesHumansTenofovirRisk FactorsAdenineAntiviral AgentsHeart Disease Risk Factors

Stichwörter der Autor:innen

Good health and well-beingHBVSDG 3TAFTDF

Substanzen

TenofovirAdenineAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver, National Sun Yat-sen University, Kaohsiung, Taiwan.

Förderung

  • Ministry of Education

Zitieren

APA

Cheng, P. N., & Yu, M. L. (2024). Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0115

Vancouver

Cheng PN, Yu ML. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2024.0115

BibTeX
@article{Cheng2024,
  author = {Cheng, Pin-Nan and Yu, Ming-Lung},
  title = {Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  doi = {10.3350/cmh.2024.0115}
}
Kostenlos starten →